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Abstract
Hedgehog (HH) signalling is important for specific developmental processes, and aberrant,
increased activity has been described in various tumours. Disturbed HH signalling has also
been implicated in the hereditary syndrome, Multiple Osteochondromas. Indian Hedgehog
(IHH), together with parathyroid hormone-like hormone (PTHLH), participates in the
organization of growth plates in long bones. PTHLH signalling is absent in osteochondromas,
benign tumours arising adjacent to the growth plate, but is reactivated when these tumours
undergo malignant transformation towards secondary peripheral chondrosarcoma. We
describe a gradual decrease in the expression of Patched (PTCH ) and glioma-associated
oncogene homologue 1 (GLI1 ) (both transcribed upon IHH activity), and GLI2 with
increasing malignancy, suggesting that IHH signalling is inactive and PTHLH signalling is
IHH independent in secondary peripheral chondrosarcomas. cDNA expression profiling and
immunohistochemical studies suggest that transforming growth factor-β (TGF-β)-mediated
proliferative signalling is active in high-grade chondrosarcomas since TGF-β downstream
targets were upregulated in these tumours. This is accompanied by downregulation of energy
metabolism-related genes and upregulation of the proto-oncogene jun B. Thus, the tight
regulation of growth plate organization by IHH signalling is still seen in osteochondroma, but
gradually lost during malignant transformation to secondary peripheral chondrosarcoma
and subsequent progression. TGF-β signalling is stimulated during secondary peripheral
chondrosarcoma progression and could potentially regulate the retained activity of PTHLH.
Copyright  2006 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Hedgehog (HH) signalling plays an important role dur-
ing embryonic and postembryonic development, where
it regulates cell proliferation and/or differentiation [1].
Upon binding to HH, Patched (PTCH) relieves its inhi-
bition of Smoothened (SMO), which activates glioma-
associated oncogene homologue (GLI) transcription
factor family members (GLI1–3). This leads to activa-
tion of target genes, including GLI1 and PTCH itself
[2,3]. In the growth plate, Indian Hedgehog (IHH) reg-
ulates chondrocyte proliferation and differentiation in
a tightly regulated paracrine feedback loop, together
with parathyroid hormone-like hormone (PTHLH or
PTHrP; Figure 1A) [4–6].
Deregulated IHH signalling has been implicated in
patients with Multiple Osteochondromas [7–9], an
autosomal dominant disorder characterized by the for-
mation of cartilage-capped, benign, bony neoplasms
on the outer surface of bones preformed by endochon-
dral ossification [8,10]. EXT1 and EXT2 have been
identified as tumour suppressor genes for Multiple
Osteochondromas [11]. These genes are involved in
the biosynthesis of heparan sulphate proteoglycans
[12,13], multifunctional macromolecules involved in
the diffusion of HH to PTCH [9,14]. Osteochondromas
also occur as solitary lesions in a non-hereditary back-
ground [10]. The cartilage cap of osteochondromas
morphologically recapitulates the epiphyseal growth
plate [10].
A small fraction (<3%) of osteochondromas trans-
forms into so-called secondary peripheral chondrosar-
comas [15,16], which are classified histologically into
three grades that correlate with prognosis [17]. Chon-
drosarcomas can recur at a higher histological grade
[15], suggesting progression in malignancy with time.
Recent findings have linked upregulated HH sig-
nalling to various human diseases [2], such as Gor-
lin syndrome, in which HH signalling is constitu-
tively active as a result of inactivating mutations in
PTCH [18]. Moreover, constitutively active HH sig-
nalling has been found in several sporadic cancers,
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Figure 1. Schematic representations of signalling pathways in growth plate, osteochondromas, and chondrosarcomas.
(A) IHH/PTHLH signalling in the postnatal growth plate. The IHH/PTHLH feedback loop is confined to the growth plate. In
the transition zone, IHH will bind PTCH, relieving its inhibitory effect on Smoothened (SMO). SMO then activates the transcription
factor GLI2, which subsequently moves to the nucleus to start transcription of IHH target genes. One of these targets is PTHLH.
After PTHLH binds to its receptor PTHR1, Bcl-2 is upregulated, inhibiting chondrocyte differentiation (adapted from [4–6,34]).
If EXT proteins are defective or absent, heparan sulphate proteoglycan expression at the cell surface may be altered or absent,
affecting the diffusion of IHH to its receptor. IHH signalling molecules are indicated in red, PTHLH signalling molecules in blue, and
molecules investigated by quantitative reverse transcriptase polymerase chain reaction (qPCR) by ∗. (B) Schematic representation
of changes in extracellular matrix, cellularity, and the expression of signalling pathways in the course of malignant transformation
of osteochondromas and subsequent progression of peripheral chondrosarcoma. The different tumour types are represented
by their histology. Malignant transformation of osteochondromas and further progression of peripheral chondrosarcoma are
characterized by a decrease in chondroid matrix and an increase in cellularity, and the strict organization seen in growth plate
is lost. In osteochondromas, there is IHH, canonical Wnt, and TGF-β signalling but no PTHLH signalling. During malignant
transformation of tumour cells that have escaped from the tight control of IHH, PTHLH signalling is activated, but Wnt signalling
decreases. During the progression of grade I towards grade III lesions, IHH signalling gradually diminishes and Wnt signalling is
lost. The proliferative TGF-β signalling pathway is upregulated during progression and activates target genes needed to acquire a
more malignant phenotype
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including sporadic basal cell carcinoma [19], medul-
loblastoma [20], colon cancer [21], small-cell lung
cancer [22], and prostate cancer [23]. Inactivation of
HH signalling has been associated with developmen-
tal malformations such as cyclopia and holoprosen-
cephaly [2].
The involvement of IHH signalling in tumouri-
genesis as well as endochondral ossification points
to its possible involvement in osteochondroma and
chondrosarcoma. We have previously demonstrated
that molecules downstream in the IHH/PTHLH sig-
nalling pathway are not expressed in osteochondromas
[24,25], suggesting that growth signalling is disturbed.
Malignant transformation leads to re-expression of
these signalling molecules [24,25].
Here, we aimed at elucidating the role of IHH
signalling in the progression of peripheral chon-
drosarcomas, in a series of hereditary and spo-
radic osteochondromas, as well as chondrosarco-
mas. The same series was subjected to genome-wide
expression analysis to identify other signal transduc-




Fresh frozen samples were obtained from resected
specimens (Table 1). Growth plates were acquired
from resections or biopsies for orthopaedic clinical
conditions not related to osteochondroma or chon-
drosarcoma. All tissue samples were handled in a
coded fashion, according to Dutch national ethical
guidelines (‘Code for Proper Secondary Use of Human
Tissue’, Dutch Federation of Medical Scientific Soci-
eties).
RNA isolation
RNA was isolated from tumour samples that contained
at least 70% tumour cells, as determined by haema-
toxylin and eosin stained frozen sections, as described
previously [26]. From L-493, RNA was isolated from
two different parts of the tumour (one part correspond-
ing to a low-grade area and the other with high-grade
morphology), to investigate possible differences in
gene expression within one tumour.
Table 1. Clinicopathological and tumour data
Sample Material∗ MO† /solitary Location Gender Age (years) Included in experiments‡
GP-29 GP — Knee Female 12 Array, qPCR
GP-53 GP — Hip Female 12 Array, qPCR
GP-62 GP — Femur Female 8 Array, qPCR§
GP-67 GP — Unknown Male 12 Array, qPCR
L-298 OC MO Pelvis Male 24 Array, qPCR
L-524 OC MO Fibula Male 27 Array
L-657 OC Solitary Femur Female 12 Array, qPCR§
L-673 OC Solitary Humerus Male 12 qPCR
L-841 OC MO Femur Female 14 Array, qPCR§
L-1235 OC MO Radius Female 5 Array, qPCR§
L-1247 OC Solitary Femur Male 30 qPCR
L-114 PCS-I MO Femur Male 39 qPCR
L-144 PCS-I Solitary Scapula Male 28 Array
L-163 PCS-I Solitary Tibia Male 49 Array, qPCR
L-626 PCS-I Solitary Femur Male 21 Array, qPCRd
L-627 PCS-I Solitary Scapula Female 31 Array, qPCR
L-724 PCS-I Solitary Ilium Female 82 Array, qPCR
L-739 PCS-I Solitary Pubis Male 37 Array, qPCR
L-758 PCS-I MO Femur Male 41 Array, qPCR
L-868 PCS-I Solitary Humerus Male 18 Array, qPCR
L-1190 PCS-I MO Humerus Female 16 qPCR
L-1245 PCS-I Solitary Fibula Male 25 Array, qPCR
L-11 PCS-II Solitary Ilium Male 49 qPCR
L-76 PCS-II Solitary Pelvis Male 47 Array, qPCR
L-123 PCS-II Solitary Femur Male 60 Array, qPCR
L-224 PCS-II Solitary Ilium Male 26 qPCR
L-308 PCS-II MO Scapula Male 42 qPCR
L-493 PCS-II Solitary Thorax Male 37 Array, qPCR§
L-1165 PCS-II Solitary Pelvis Female 37 Array, qPCR
L-281 PCS-III Solitary Scapula Female 39 Array, qPCR§
L-300 PCS-III MO Scapula Female 61 Array, qPCR§
∗ GP = growth plate; OC = osteochondroma; PCS = peripheral secondary chondrosarcoma grade I, II or III.
† MO = Multiple Osteochondromas.
‡ Array = cDNA microarray; qPCR = quantitative reverse transcriptase PCR experiments.
§ Samples used for standard curve in the qPCR experiments.
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Quantitative reverse transcriptase PCR (qPCR)
For first strand cDNA synthesis, 1 µg of total RNA
was reverse transcribed using AMV reverse transcrip-
tase (Roche, Penzberg, Germany) with 100 ng primer
(dT) 15 (Roche) and 50 ng random primers (Invitrogen
Carlsbad, CA, USA), according to the manufacturer’s
instructions.
qPCR reactions were performed as previously
described [27] with PCR primers provided as shown
in supplementary Table 1 (available at http://www.in-
terscience.wiley.com/jpages/0022-3417/suppmat/path.
2008.html). Expression levels were normalized to four
genes (CPSF6, GPR108, CAPNS1, and SRPR) selected
from expression profiling experiments of peripheral
and central [28] cartilaginous tumours, with the least
variation between all samples using the geNorm pro-
gramme [29]. Log2 transformed normalized data were
analysed in SPSS 11.0 (SPSS Inc, Chicago, IL,
USA). Expression levels in human growth plates were
compared with those in osteochondromas, low-grade
(grade I) and high-grade (grades II and III) chondrosar-
comas using one-way analysis of variance with Bon-
ferroni correction. Spearman’s non-parametric correla-
tion coefficients were computed for relations between
expression levels and histological grade. Corrected p-
values ≤0.05 were considered significant.
cDNA microarrays
A custom-made cDNA microarray was used in order
to include more genes involved in chondrogenesis.
The list of cDNA clones is available upon request.
Array production, hybridization, and image acquisition
procedures were performed as described previously
[28]. In brief, tumour and growth plate samples were
hybridized against a common reference panel of cell
lines [28,30]. For hybridization, 1 µg of sample total
RNA and 1 µg of reference panel total RNA were used
to generate biotin- and fluorescein-labelled cDNA,
using the Micromax TSA labelling kit (Perkin Elmer,
Wellesley, MA, USA). Hybridized slides were scanned
with a GeneTac LSV scanner (Genomic Solutions,
Ann Arbor, MI, USA). Experimental quality was
checked by labelling and hybridizing five samples in
duplicate, either as experimental duplicates (n = 2) or
as dye swaps (n = 3).
Data analysis
Signal intensities were recorded and quantified with
Genepix Pro 4.1 software (Axon Instruments, Union
City, CA, USA). A Microsoft Excel macro [28]
was previously created to select bona fide spots
systematically, normalize these by dividing by the
median of all bona fide spots, and log transform the
normalized spots.
Analysis was performed for genes expressed in
at least 70% of samples. Unsupervised hierarchi-
cal clustering (with ‘complete linkage’ and ‘correla-
tion’) was performed with Spotfire Decisionsite soft-
ware for functional genomics (Somerville, MA, USA).
Two methods for group comparison were used. The
first method (corrected t-test method) used the log-
transformed ratios of the Excel macro. P -values were
calculated by a two-sided Student’s t-test with unequal
variance and corrected for multiple testing using the
step-up procedure with a false discovery rate of 10%
[31]. The second method was the Limma (Linear mod-
els for Microarray Data) package [32], because of its
excellent performance in microarray analysis. Limma
used the raw Genepix data for within-array print-tip
loess normalization of intensities after the same cri-
teria for spot selection were applied, as described
in the Excel macro [28]. Identities of differentially
expressed, spotted clones were verified by sequencing
the PCR products.
Differentially expressed genes were selected for
verification by either qPCR or immunohistochemistry.
The microarray series could be expanded with seven
extra tumours (Table 1) for qPCR analysis.
Immunohistochemistry
Expression of JUNB (antibody sc-8051, Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA, dilution
1 : 150) and PAI1 (SERPINE1 protein; antibody No
3785, American Diagnostica, Stanford, CT, USA,
dilution 1 : 350) was evaluated in 18 osteochondromas,
39 chondrosarcomas, and 12 human growth plates.
Staining and scoring of 4 µm sections of formalin-
fixed, paraffin-embedded material was performed as
described [24]. Staining intensity was compared with
internal positive controls: osteoblasts and osteoclasts
for JUNB, blood vessels and connective tissue for
PAI1.
Activity of TGF-β signalling and Wnt signalling
was investigated by the presence of either nuclear
phosphorylated Smad2 (PS2 antibody, kindly donated
by P ten Dijke [33], dilution 1 : 2000) expression
or nuclear β-catenin (clone 14, BD Biosciences,
Erembodegem, Belgium, dilution 1 : 800) expression.
Osteoblasts served as positive internal control for PS2,
and osteoblasts and blood vessels for β-catenin.
A χ2 test and Spearman’s non-parametric correla-
tion were used in the statistical analysis. Values of
p ≤ 0.05 were considered significant.
Results
qPCR to detect mRNA expression of IHH
signalling molecules
Expression of seven genes involved in IHH signalling
(Figure 1A) was assayed using qPCR, and compared
with human growth plates (Table 2). Compared with
growth plates, PTCH expression was decreased in
low-grade (p = 0.039) and high-grade chondrosarco-
mas (p = 0.001) but not in osteochondromas (p =
1.00; Figure 2A). Of the GLI transcription factors,
GLI2 had the highest expression in the growth plate
J Pathol 2006; 209: 501–511 DOI: 10.1002/path
Copyright  2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
IHH and TGF-β signalling in chondrosarcomas 505
Table 2. Log2 transformed relative expression data of IHH signalling molecules in qPCR
Growth plate Osteochondroma Osteochondroma Low grade PCS∗
Low-grade
PCS vs High grade PCS
High-grade
PCS vs
(n = 4) (n = 6) vs growth plate growth plate growth plate
Genes Median† ± SD Median ± SD p-value‡ n Median ± SD p-value n Median ± SD p-value
IHH 10.94 ± 2.44 9.08 ± 2.62 1.000 9 10.34 ± 2.88 1.000 9 7.19 ± 2.65 0.166
PTCH 10.74 ± 0.54 10.22 ± 0.73 1.000 10 9.24 ± 1.38 0.039 10 7.80 ± 1.11 0.001
SMO 10.22 ± 0.49 10.33 ± 0.36 1.000 10 10.50 ± 0.66 1.000 10 9.73 ± 1.34 0.554
GLI1 9.80 ± 0.23 9.43 ± 0.75 1.000 10 8.49 ± 1.04 0.235 10 8.37 ± 1.35 0.043
GLI2 11.10 ± 0.93 9.87 ± 0.73 0.567 10 9.17 ± 1.23 0.015 10 8.62 ± 1.59 0.002
GLI3 9.65 ± 0.22 8.91 ± 0.71 1.000 10 9.04 ± 0.70 1.000 10 9.16 ± 1.00 0.475
PTHLH 7.44 ± 0.83 6.08 ± 1.11 0.620 10 5.68 ± 1.08 0.474 10 4.95 ± 1.89 0.206
∗ PCS = peripheral chondrosarcoma.
† Median = median log transformed expression level of the group.
‡ P-value after Bonferroni correction.
Figure 2. qPCR results of IHH signalling molecules. (A–C) Log-transformed relative mRNA expression levels in growth plate,
osteochondromas, and low-grade and high-grade chondrosarcomas represented in boxplots of (A) PTCH expression, (B) GLI2
expression, and (C) GLI1 expression. *Significantly lower expression compared with growth plate (p < 0.05). Diamonds = extreme
values; filled circles = outliers; PCS = peripheral chondrosarcoma
(p = 0.006) and was reduced in low-grade chondrosar-
comas (p = 0.015). Expression of both GLI2 and
GLI1 was even lower in high-grade tumours than in
growth plate (p = 0.002 and p = 0.043, respectively;
Figure 2B and C). GLI1 expression correlated with
GLI2 expression (r = 0.584, p = 0.02). GLI3 expres-
sion was not affected in tumours (Table 2).
Increasing histological grade correlated negatively
to the expression of PTCH (r = −0.600, p = 0.001),
GLI1 (r = −0.458, p = 0.018), and GLI2 (r =
−0.457, p = 0.019), suggesting gradual downregu-
lation of IHH signalling during tumour progression
(Figure 1B). Expression of PTCH (r = −0.810, p <
0.001), GLI1 (r = −0.524, p = 0.006), and GLI2
(r = −0.421, p = 0.032) correlated negatively with
patient age (supplementary Figure 1, available at
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2008.html), gradually diminishing over
40 years. Using age as a covariate in the analysis,
the difference in expression between growth plates
and chondrosarcomas was only significant for GLI2
(p = 0.034).
For the grade II chondrosarcoma L-493, two sepa-
rate tissue samples were used. Expression data from
the matrix-rich sample were similar to those of low-
grade tumours, while results from the more cellular
and myxoid sample corresponded to those of high-
grade chondrosarcomas. PTHLH mRNA expression
was present in all tumours. PTHLH protein expres-
sion data, as determined previously [24], was available
for four osteochondromas and 14 chondrosarcomas,
and correlated with the mRNA expression (r = 0.53,
p = 0.01).
Expression profiling
To identify signal transduction pathways that might
be alternatives to IHH signalling, genome-wide cDNA
microarray analysis was performed on 20 tumours
and four growth plates. Hierarchical cluster analy-
sis showed that technical duplicates and dye swaps
cluster together (supplementary Figure 2, available at
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2008.html), assuring technical repro-
ducibility and absence of dye bias as well as microar-
ray quality. Duplicate spotted clones showed optimal
correlation as well. The samples from L-493 with dif-
ferent histology did not cluster together, in contrast
to technical duplicates from other samples, complying
with the aforementioned qPCR results. Unsupervised
clustering showed no distinct clusters of tumour sam-
ples, indicating that the different histological grades
are characterized by more subtle changes in gene
expression. Despite the good overall quality of the
microarray, 20 cDNA clones of genes involved in IHH
and PTHLH signalling were suboptimal and could
J Pathol 2006; 209: 501–511 DOI: 10.1002/path
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(n = 4) (n = 6) PCS-I∗ (n = 10) PCS-II (n = 8) PCS-III (n = 2)
Genes Median‡ ± SD Median ± SD Median ± SD Median ± SD Median ± SD r p-value
ALDOA 7.50 ± 0.41 7.61 ± 0.51 8.47 ± 0.74 8.47 ± 0.25 7.89 ± 0.02 0.509 0.013
COX8A 8.39 ± 0.54 7.89 ± 0.61 8.55 ± 0.58 8.26 ± 0.67 8.19 ± 0.27 0.014 0.948
NDUFB8 11.73 ± 0.32 11.63 ± 0.71 11.98 ± 1.71 10.36 ± 0.81 10.39 ± 0.33 0.409 0.052
NDUFS3 8.50 ± 0.94 8.53 ± 0.79 8.36 ± 1.09 6.98 ± 0.69 7.13 ± 0.82 0.195 0.372
PLOD3 4.87 ± 0.44 5.18 ± 0.92 6.07 ± 0.74 6.42 ± 0.53 6.66 ± 0.38 0.579 0.004
FN1 11.36 ± 0.84 10.73 ± 1.13 10.61 ± 1.10 11.06 ± 1.29 13.50 ± 0.31 0.552 0.006
∗ PCS = peripheral chondrosarcoma.
† Correlation of qPCR expression data with microarray expression data available for four growth plates, four osteochondromas, eight grade I,
five grade II, and two grade III chondrosarcomas.
‡ Median = median log transformed expression level of the group.
therefore not be optimally correlated to the qPCR
results of these genes.
Limma analysis revealed 17 differentially expressed
cDNA clones between osteochondromas and human
growth plates (supplementary Table 2, available at
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2008.html). Fourteen clones were more
highly expressed in osteochondromas, including multi-
ple clones encoding the proto-oncogene jun B (JUNB )
and several metallothionein 1 (MT1 ) genes.
We did not find any significantly differentially
expressed genes in the comparison of osteochondroma
and grade I chondrosarcoma.
A comparison of grade I and grade III chon-
drosarcomas for analysis of tumour progression
identified 79 differentially expressed genes with
the corrected t-test method and 32 with the
Limma package (supplementary Table 3, available at
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2008.html). Eleven genes were present
in both analyses. Several genes involved in TGF-β
signalling were upregulated in grade III chon-
drosarcomas: fibronectin 1(FN1 ); serine (or cys-
teine) proteinase inhibitor, clade E (nexin, plasmino-
gen activator inhibitor type 1), member 1 (SER-
PINE1 ); thrombospondin 1 (THBS1 ); and cyclin-
dependent kinase inhibitor 1A (CDKN1A, p21,
CIP1 ). TGF-β1 was upregulated in high-grade chon-
drosarcomas (supplementary Table 3, available at
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2008.html). Several genes involved in
extracellular matrix remodelling were upregulated;
among the downregulated genes (corrected t-test n =
23; Limma n = 5) were those encoding the α1 chains
of type IX collagen(COL9A1 ) and type II colla-
gen (COL2A1 ). Additionally, several genes encod-
ing proteins involved in oxidative phosphorylation
were downregulated in grade III chondrosarcomas.
These included genes encoding NADH dehydroge-
nase (ubiquinone) 1 β subcomplex, 8 (NDUFB8 ), a
component of complex I, and cytochrome c oxidase
subunit 8A (COX8A) of complex IV. Also, glycolytic
enzyme aldolase C (ALDOC ), part of the glycolysis,
was downregulated in grade III chondrosarcomas com-
pared with grade I lesions.
qPCR verification of cDNA microarray results
To confirm the differences in mRNA expression
of genes relevant to TGF-β signalling, extracellu-
lar matrix, and oxidative phosphorylation found in
the progression analysis, we performed qPCR on
four genes representing these groups (Table 3). The
qPCR results for FN1, PLOD3, and NDUFB8 corre-
lated with the microarray expression data (p = 0.006,
p = 0.004 and p = 0.052, respectively). No correla-
tion was found for COX8A (p = 0.948). FN1 was
upregulated in grade III chondrosarcomas compared
with osteochondromas, and grade I and II chondrosar-
comas (p = 0.011, 0.014, and 0.012, respectively).
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
(PLOD3 ) expression was significantly positively cor-
related with increasing histological grade (r = 0.506,
p = 0.008), while NDUFB8 showed a negative corre-
lation (r = −0.391, p = 0.049). Additionally, mRNA
expression of NADH dehydrogenase (ubiquinone) Fe-
S protein 3 (NDUFS3 ) of oxidative phosphorylation
complex I, and aldolase A (ALDOA) of glycolysis were
analysed. Similarly to NDUFB8, NDUFS3 expres-
sion was negatively correlated with tumour progres-
sion (r = −0.529, p = 0.005). Expression of COX8
and ALDOA decreased with progression. ALDOA was
upregulated in grade I chondrosarcomas in comparison
with osteochondromas (p = 0.024).
Immunohistochemical analysis of protein
expression
SERPINE1 and JUNB microarray expression data
were verified by immunohistochemistry (Table 4).
The sum score of PAI1 (SERPINE1 protein) cor-
related with the mRNA expression (r = 0.488, p =
0.047) and with increasing histological grade (r =
0.447, p < 0.001, Figure 3A–C).
For 16 samples (two human growth plates, three
osteochondromas, and five grade I, four grade II,
and two grade III chondrosarcomas), also included
J Pathol 2006; 209: 501–511 DOI: 10.1002/path
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Figure 3. Immunohistochemical results. (A) Low-power view of an osteochondroma with weak PAI1 protein staining in less
than 25% of the cells. Note the positive blood vessels, used as internal positive control; (B) a grade II chondrosarcoma with
strong cytoplasmic PAI1 protein staining in 75–100% of the cells; (C) Boxplot of total scores from the semiquantitative scoring of
PAI1 protein expression. There is a significant positive correlation between progression and PAI1 protein expression (r = 0.447,
p < 0.001). (D) Low-power view of an osteochondroma demonstrating weak nuclear JUNB protein expression in 25–50% of the
cells; (E) grade I chondrosarcoma with moderate nuclear JUNB protein expression in 75–100% of the cells; (F) strong nuclear
JUNB expression was found in most cells in this grade II chondrosarcoma. (G) Low-power view of a human epiphyseal growth plate
with strong nuclear and cytoplasmic phosphorylated Smad2 staining in the proliferating and hypertrophic chondrocytes, whereas
the resting chondrocytes are negative; (H) peripheral chondrosarcoma grade II with strong phosphorylated Smad2 expression in
the majority of tumour cells. The same was observed in grade III chondrosarcomas (I)







Growth plate 1/10 (0/2) 10 (0)
Osteochondroma 9/18 (2/3) 50 (67) 5/13 (1/3) 38 (33)
PCS grade I 15/23 (5/8) 65 (63) 7/22 (3/5) 32 (60)
PCS grade II 12/13 (4/4) 92 (100) 7/12 (2/4) 58 (50)
PCS grade III 3/3 (2/2) 100 (100) 3/3 (2/2) 100 (100)
∗ Number of positive tumours/total number of tumours that could be
evaluated. Data for the tumours for which cDNA array analysis was
also available are shown in parentheses.
† Five osteochondromas and nine chondrosarcomas could not evaluated
because the internal positive controls were negative.
in the microarray experiments, JUNB protein expres-
sion correlated with the mRNA expression (r = 0.544,
p = 0.016). Expression analysis revealed differential
expression of JUNB mRNA between growth plate
and osteochondroma. When comparing growth plates
and osteochondromas for JUNB protein expression,
no difference was observed (Fisher’s exact test,
p = 0.179). The number of JUNB-positive tumours
correlated significantly with increasing histological
grade (χ2, linear-by-linear, p = 0.005, Figure 3D–F,
Table 4).
In human growth plates, both cytoplasmic and
nuclear expression of phosphorylated Smad2 was
observed in proliferating and hypertrophic chondro-
cytes (Figure 3G). Expression was variable in rest-
ing chondrocytes. Nuclear and cytoplasmic expression
of phosphorylated Smad2 was observed in all osteo-
chondromas and chondrosarcomas (Figure 3H and I),
implicating active TGF-β signalling (Figure 1B).
Nuclear expression of β-catenin, was found for 9/17
(53%) osteochondromas, 4/21 (19%) grade I chon-
drosarcomas, and in the hypertrophic zone of 5/12
(42%) human growth plates, but not in 11 grade II
and two grade III chondrosarcomas. This indicated that
canonical Wnt signalling decreased with increasing
malignancy (χ2p = 0.020; Figure 1B). Twenty-two
J Pathol 2006; 209: 501–511 DOI: 10.1002/path
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tumours also included in the frozen series demon-
strated a positive correlation between PTCH expres-
sion and nuclear expression of β-catenin (r = 0.567,
p = 0.006).
Discussion
This study shows that mRNA expression of IHH
downstream targets is gradually downregulated dur-
ing tumour progression in peripheral chondrosarcoma
compared with normal growth plates, from which its
benign precursor, osteochondroma, originates. Expres-
sion of both PTCH and GLI1, two genes transcribed
upon activation of HH signalling [3], correlated neg-
atively with increasing histological grade. This was
also found for GLI2, which transduces the IHH sig-
nal during endochondral bone development [34], but
is not a known downstream target of IHH. Recently,
GLI3 has been identified as a key effector of IHH sig-
nalling during cartilage development [35], where IHH
antagonizes the repressor activity of GLI3 on PTHLH
expression and proliferation. However, in chondrosar-
comas, GLI3 expression was similar to the expression
seen in human growth plate (Table 2). Therefore, there
was no indication that GLI3 plays a role in chondrosar-
coma progression.
Recently, constitutively active IHH signalling was
demonstrated in chondrosarcoma explants [36]. These
contradictory results could be partly explained by the
selection of housekeeping genes for qPCR analysis.
This has been shown to be tissue type specific [29],
which led us to choose genes based upon the expres-
sion array results, instead of choosing random, non-
tumour-specific genes, like GAPDH, which was not
stably expressed in cartilaginous tumours. Also, no
discrimination was made by Tiet et al between periph-
eral and central-type chondrosarcomas, [36] even
though it was previously shown that these subtypes
clearly have a different genetic make-up [37,38] and
other distinct pathways might be operative.
IHH signalling has been shown to be upstream
of canonical Wnt signalling cascades required for
osteogenic differentiation [39]. Wnt signalling appears
to be involved in chondrogenic differentiation, since
we could demonstrate decreased nuclear expres-
sion of β-catenin during chondrosarcoma progression
(Figure 1B). This intriguing potential relation between
IHH and Wnt signalling in chondrogenesis needs fur-
ther studies.
EXT1 and EXT2 are of importance for the diffu-
sion of IHH to its receptor [9,14,40]. Consequently,
there is a strong indication that IHH signalling is
important in osteochondroma formation. Here we have
demonstrated that the expression of IHH signalling in
osteochondromas did not differ from the expression
found in growth plates. Morphologically, osteochon-
dromas strongly resemble the epiphyseal growth plate
[10], and different zones of endochondral ossification
can sometimes be distinguished. It was not technically
possible to dissect these different layers to investigate
zone-specific expression of IHH signalling molecules.
This probably also affects expression levels of genes
that are only expressed in a specific layer.
Similar to growth plates, osteochondromas cease to
grow after puberty [10]. Therefore, we investigated the
putative relationship between mRNA levels of IHH
signalling molecules in tumours and patient age, and
demonstrated decreasing expression of PTCH, GLI1,
and GLI2 over a period of 40 years. However, the
observation that diagnosis correlates with age [41], and
the distinct expression profiles of low-grade and high-
grade tumours of patients with the same age (including
the two samples from L-493), suggest that expression
of PTCH, GLI1, and GLI2 does correlate with tumour
progression.
Despite inactivation of IHH signalling, there is
active, IHH-independent PTHLH signalling in chon-
drosarcomas (Figure 1B) [4,24]. This is similar to the
finding in central chondrosarcomas [27], but not to
murine growth plate, where IHH has been shown to
directly regulate PTHLH expression [42]. Our results
showed a discrepancy between PTHLH mRNA and
previously published protein expression [24]. However
PTHLH mRNA has a very short half-life [43], making
it difficult to correlate protein and gene expression.
A good candidate to activate PTHLH signalling
in the absence of IHH is TGF-β, which can regu-
late PTHLH expression independently of IHH [44].
Genome-wide expression profiling experiments reveal-
ed that tumour progression was indeed associated with
upregulation of genes involved in TGF-β signalling,
including TGF-β1, comparable to results found in
other tumours [45]. Expression of FN1, SERPINE1,
and THBS1 was upregulated in grade III chondrosar-
comas (Tables 3 and 4). These genes are known down-
stream targets of TGF-β signalling and are signifi-
cant in regard to tumour invasion and metastasis [46].
Upregulation of the TGF-β downstream cell cycle
inhibitor CDKN1A has previously been noted at the
protein level [24]. The changes observed in extra-
cellular matrix-related genes could also be regulated
by TGF-β. Taken together, these results implied that
TGF-β signalling is activated in high-grade chon-
drosarcomas and this conclusion was supported by the
presence of nuclear phosphorylated Smad2 in these
tumours. Phosphorylated Smad2 was also present in
osteochondromas and human growth plates. For the
latter the expression pattern was similar to that of
unphosphorylated Smad2 in rat epiphyseal growth
plate [47]. One can hypothesize that in chondrosar-
comas TGF-β activates specific target genes needed
to acquire a malignant phenotype. The possibility
cannot be excluded that some of these differentially
expressed genes, like THBS1 and FN1, are the result
of increased vascularization in high-grade chondrosar-
comas [48,49].
The diminished amounts of chondroid matrix in
high-grade chondrosarcomas [15] and its lack of
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cellular organization in comparison with osteochon-
droma suggest loss of the IHH/PTHLH feedback loop
(Figure 1). IHH signalling is a tightly controlled sig-
nalling pathway. We observed that osteochondroma
cells are still controlled by IHH and undergo endo-
chondral ossification. As the osteochondroma ages,
IHH signalling decreases, which was also seen in the
growth plate [50], and all tumour cells will eventu-
ally differentiate. One can hypothesize that tumour
cells may escape from IHH control to transform into
a malignancy, by switching to less controlled prolifer-
ative signalling pathways, such as TGF-β signalling,
thereby causing a cascade of events resulting in tumour
progression (Figure 1B). To explore this hypothesis
further, a model system would be helpful, but this is
hampered by differences between humans and rodents,
in which there is no closure of the growth plate at the
end of sexual maturation [51].
Further analysis of the genome-wide expression
studies revealed decreased expression of genes that
encode proteins involved in oxidative phosphorylation
and glycolysis in grade III chondrosarcomas com-
pared with grade I chondrosarcomas. Glycolysis is
upregulated in hypoxic environments, such as pauci-
vascular osteochondromas and low-grade chondrosar-
comas [10,15], giving cells a growth advantage [52].
High-grade chondrosarcomas show increased vascu-
larization [48,49], which will raise oxygen availabil-
ity and thereby abolish the need for glycolysis. This
was reflected by the downregulation of ALDOA and
ALDOC in grade III chondrosarcomas.
Oxidative phosphorylation was simultaneously
downregulated with glycolysis. In otherwise non-
invasive C2C12 myoblasts, depletion of mitochon-
drial DNA induces an invasive phenotype [53] and
increases resistance to apoptosis, in part by upregulat-
ing Bcl-2 [54]. High-grade chondrosarcomas have high
Bcl-2 expression [24] and an increased risk of recur-
rence and metastasis [15], consistent with an invasive
phenotype.
The expression profiles of osteochondromas and
grade I chondrosarcomas were indistinguishable. This
distinction is also considered difficult at the histolog-
ical level and is usually based on a combination of
histological, radiological, and clinicopathological data
[15]. Most likely the differences in gene expression
are very subtle or only detectable at the protein level
and cannot be detected with the method used.
Both qPCR and genome-wide expression profiling
revealed similarities in gene expression between osteo-
chondromas and human epiphyseal growth plates.
However, JUNB (and to lesser extent FOSB ) were
more highly expressed in osteochondromas than in
growth plates. JUNB and FOSB are members of
the AP-1 transcription factor family, which has
been implicated in endochondral ossification in mice
[55,56]. Remarkably, we found very low levels of
JUNB mRNA and protein in growth plates. JUNB can
have a stimulatory effect on chondrocyte proliferation
[55]. At the protein level, JUNB gradually increased
during malignant transformation and further progres-
sion, which is consistent with its effect on prolifera-
tion. This increase in JUNB expression might also be
regulated by TGF-β [57].
In conclusion, IHH signalling controls the tight reg-
ulation of growth plate organization and is still active
in osteochondroma. However, IHH signalling is grad-
ually inactivated during peripheral chondrosarcoma
progression when tumour cells adapt to a more malig-
nant phenotype (Figure 1B). TGF-β signalling can
potentially regulate PTHLH signalling and concurrent
remodelling of the extracellular matrix. Downregula-
tion of genes involved in oxidative phosphorylation
and glycolysis accompanies the more invasive pheno-
type of high-grade tumours.
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